Logo image of TTNP

TITAN PHARMACEUTICALS INC (TTNP) Stock Fundamental Analysis

USA - NASDAQ:TTNP - US8883147055 - Common Stock

4.61 USD
-0.18 (-3.76%)
Last: 10/1/2025, 9:36:58 PM
5.91 USD
+1.3 (+28.2%)
After Hours: 10/1/2025, 9:36:58 PM
Fundamental Rating

2

TTNP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. The financial health of TTNP is average, but there are quite some concerns on its profitability. TTNP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TTNP had negative earnings in the past year.
TTNP had a negative operating cash flow in the past year.
TTNP had negative earnings in each of the past 5 years.
In the past 5 years TTNP always reported negative operating cash flow.
TTNP Yearly Net Income VS EBIT VS OCF VS FCFTTNP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

TTNP has a worse Return On Assets (-161.00%) than 84.18% of its industry peers.
TTNP has a Return On Equity of -192.87%. This is in the lower half of the industry: TTNP underperforms 69.39% of its industry peers.
Industry RankSector Rank
ROA -161%
ROE -192.87%
ROIC N/A
ROA(3y)-160.51%
ROA(5y)-163.38%
ROE(3y)-341.83%
ROE(5y)-342.56%
ROIC(3y)N/A
ROIC(5y)N/A
TTNP Yearly ROA, ROE, ROICTTNP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

TTNP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TTNP Yearly Profit, Operating, Gross MarginsTTNP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

TTNP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TTNP has more shares outstanding
The number of shares outstanding for TTNP has been increased compared to 5 years ago.
TTNP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TTNP Yearly Shares OutstandingTTNP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
TTNP Yearly Total Debt VS Total AssetsTTNP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -186.45, we must say that TTNP is in the distress zone and has some risk of bankruptcy.
TTNP has a worse Altman-Z score (-186.45) than 94.39% of its industry peers.
TTNP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -186.45
ROIC/WACCN/A
WACC9.9%
TTNP Yearly LT Debt VS Equity VS FCFTTNP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 6.05 indicates that TTNP has no problem at all paying its short term obligations.
The Current ratio of TTNP (6.05) is better than 74.49% of its industry peers.
A Quick Ratio of 6.05 indicates that TTNP has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.05, TTNP is doing good in the industry, outperforming 74.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.05
Quick Ratio 6.05
TTNP Yearly Current Assets VS Current LiabilitesTTNP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

TTNP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.34%, which is quite impressive.
The Revenue for TTNP has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)29.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TTNP Yearly Revenue VS EstimatesTTNP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
TTNP Yearly EPS VS EstimatesTTNP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 0 -1K -2K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TTNP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TTNP Price Earnings VS Forward Price EarningsTTNP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TTNP Per share dataTTNP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TTNP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TITAN PHARMACEUTICALS INC

NASDAQ:TTNP (10/1/2025, 9:36:58 PM)

After market: 5.91 +1.3 (+28.2%)

4.61

-0.18 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13
Earnings (Next)01-01 2026-01-01
Inst Owners3.56%
Inst Owner Change156.26%
Ins Owners29.69%
Ins Owner Change0%
Market Cap6.13M
Analysts43.33
Price TargetN/A
Short Float %5.28%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-5.23
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.92
FCFYN/A
OCF(TTM)-2.92
OCFYN/A
SpS0
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161%
ROE -192.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-160.51%
ROA(5y)-163.38%
ROE(3y)-341.83%
ROE(5y)-342.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.05
Quick Ratio 6.05
Altman-Z -186.45
F-Score3
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.89%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.29%
OCF growth 3YN/A
OCF growth 5YN/A